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We are responding to the original article by Roche and colleagues (1) and subsequent 
correspondence (2, 3) about the effects of dual bronchodilator therapy on COPD exacerbations and the 
potential role of eosinophils in determining the differential benefit over an ICS/LABA combination. 
Professor Roche and his colleagues reiterate the view that eosinophil counts make no difference in 
determining this differential response. We feel they are not acknowledging what is actually shown by 
the data. 
Figures 1 and 2 in the original paper (1) clearly demonstrate that the differential benefit, in terms of 
exacerbation rate ratio and hazard ratio, of dual bronchodilator therapy over an ICS/LABA combination 
therapy, becomes numerically less with higher eosinophil counts in a convincing step-wise fashion. In 
addition, there is no statistically significant difference in the rate ratio when the blood eosinophil count 
exceeds 3% or 150 cells/mcl and no difference in the hazard ratio (which is the most robust 
exacerbation metric) between the two treatments when the blood eosinophil count exceeds 5% or 300 
cells/mcl. Also, it is important to note that in the FLAME study COPD patients with eosinophil levels 
above 600/µL were excluded, as well as patients with a history of asthma or concomitant allergic 
rhinitis. We believe that, if these types of patients been included, the influence of eosinophils would 
have been even more obvious. 
Thus, one must conclude that eosinophil count is an important determinant of the relative 
effectiveness of dual bronchodilator therapy over an ICS/LABA combination therapy in terms of reducing 
moderate and severe COPD exacerbations. We are not presented wth a breakdown of exacerbation 
types and are thus not able to determine whether the relationship between treatment efficacy and 
blood eosinophil count differs for episodes treated with antibiotics alone compared to those treated 
with oral corticosteroids (OCS) . This is an important omission, as an earlier study (4) showed that OCS 
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treated events were more effectively inhibited by ICS/LABA than long-acting antimuscarinic treatment 
whereas the reverse was true for episodes treated with antibiotics alone.  
A final important point is that the conclusions drawn from the FLAME study (5) are being regarded 
as synonymous with differences in pharmacology. However, clearly the comparison involved different 
molecules with different devices and different frequency of administration. Without adherence data the 
comparison is of limited value. 
There is now general acceptance, among COPD specialists, that dual bronchodilator therapy has 
significant and clinically important benefits in reducing exacerbation risk in COPD patients. The FLAME 
study (5) is undoubtedly a convincing in this regard, but the results are really not surprising. Previously, 
it had been demonstrated that dual bronchodilators produced greater improvement in pulmonary 
function compared with ICS/LABA (6), and reduced exacerbation risk is strongly associated with 
improved FEV1 (7). Therefore, comparing two bronchodilators with a combination therapy that contains 
only one is not a really a fair comparison. Furthermore, this is not the main point of contention. 
No-one is arguing that ICS plus LABA is superior to LAMA plus LABA with regard to reducing 
exacerbation risk. However, we should acknowledge that ICS/LABA combination therapies also clearly 
reduce the risk of exacerbations in COPD patients (8) and a wealth of evidence now shows that this 
benefit is greater with higher eosinophil counts (9, 10). This is exactly the reason why the differential 
benefit of dual bronchodilator therapy over ICS/LABA reported by Roche, et al (1) is less with higher 
eosinophil count and actually why there is no difference above certain eosinophil levels. 
Moving on from FLAME, let us agree that dual bronchodilator therapy should be regarded as 
foundational therapy for all symptomatic patients with COPD and that higher eosinophil counts can help 
identify those patients who are more likely to respond favorably to inhaled corticosteroids (11). 
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